The dual actions of GLP-1 RAs, namely, the promotion of insulin secretion and the inhibition of glucagon release, exert a significant influence on the plasma ratio of these hormones, thereby contributing to the maintenance of glucose homeostasis in the body
The FDA looks for conclusive evidence that these drugs are both effective and safe at treating obesity in people, with or without diabetes
What are the side effects of GLP-1 therapy, and does microdosing reduce them
Because retatrutide remains in clinical trials, its full side-effect profile has not been comprehensively established through post-marketing surveillance
The Ultra-High Efficacy Seeker: Patients needing the absolute maximum weight reduction to meet surgical qualification criteria or to reverse severe comorbidities
Medicaid & Medi-Cal patients cannot use Midis services. This is a hard gate for those populations and is worth knowing before committing to the registration flow
